|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.52 | 88.89 | 103.80 | 0.54 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
155.45
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | -0.24 | 0.60 | 1.29 | 0.86 | 0.31 | CEPS(Rs) | 0.12 | 0.98 | 1.66 | 1.22 | 0.60 | DPS(Rs) | 0.00 | 0.00 | 0.50 | 0.00 | 0.20 | Book NAV/Share(Rs) | 40.18 | 40.02 | 41.14 | 35.11 | 36.41 | Tax Rate(%) | 37.62 | 5.68 | 21.46 | 6.45 | -22.30 | Margin Ratios | | | | | | Core EBITDA Margin(%) | -11.73 | -5.43 | 8.92 | 8.93 | 1.61 | EBIT Margin(%) | -3.21 | 7.85 | 16.21 | 12.14 | 5.66 | Pre Tax Margin(%) | -4.33 | 7.12 | 15.22 | 9.94 | 3.72 | PAT Margin (%) | -2.70 | 6.72 | 11.95 | 9.30 | 4.55 | Cash Profit Margin (%) | 1.35 | 11.07 | 15.35 | 13.20 | 8.89 | Performance Ratios | | | | | | ROA(%) | -0.53 | 1.30 | 3.01 | 2.10 | 0.75 | ROE(%) | -0.61 | 1.47 | 3.39 | 2.41 | 0.83 | ROCE(%) | -0.68 | 1.65 | 4.45 | 2.96 | 0.99 | Asset Turnover(x) | 0.20 | 0.19 | 0.25 | 0.23 | 0.16 | Sales/Fixed Asset(x) | 2.01 | 2.04 | 2.66 | 2.66 | 3.00 | Working Capital/Sales(x) | 16.78 | 3.37 | 5.55 | 12.27 | 22.11 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 0.50 | 0.49 | 0.38 | 0.38 | 0.33 | Receivable days | 53.54 | 94.31 | 69.43 | 66.55 | 132.93 | Inventory Days | 93.97 | 94.25 | 52.44 | 45.13 | 42.89 | Payable days | 126.58 | 195.35 | 206.34 | 188.80 | 148.84 | Valuation Parameters | | | | | | PER(x) | 0.00 | 224.56 | 186.31 | 90.43 | 233.81 | PCE(x) | 596.59 | 136.24 | 145.08 | 63.71 | 119.79 | Price/Book(x) | 1.81 | 3.34 | 5.86 | 2.21 | 1.97 | Yield(%) | 0.00 | 0.00 | 0.21 | 0.00 | 0.28 | EV/Net Sales(x) | 8.22 | 15.14 | 22.56 | 8.63 | 10.92 | EV/Core EBITDA(x) | 972.14 | 123.67 | 108.36 | 53.30 | 109.10 | EV/EBIT(x) | -252.95 | 192.24 | 137.44 | 70.42 | 192.71 | EV/CE(x) | 1.60 | 2.89 | 5.29 | 1.96 | 1.76 | M Cap / Sales | 8.13 | 15.13 | 22.54 | 8.49 | 10.67 | Growth Ratio | | | | | | Net Sales Growth(%) | 1.39 | -17.26 | 16.77 | 36.73 | 56.84 | Core EBITDA Growth(%) | -93.00 | -51.33 | 50.16 | 121.09 | 182.92 | EBIT Growth(%) | -141.81 | -60.29 | 56.45 | 195.53 | 793.18 | PAT Growth(%) | -141.08 | -53.92 | 50.48 | 181.32 | 444.19 | EPS Growth(%) | -140.91 | -53.92 | 50.49 | 179.60 | 439.93 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | 0.02 | 0.02 | 0.01 | 0.04 | 0.05 | Current Ratio(x) | 1.19 | 1.73 | 1.50 | 1.18 | 1.09 | Quick Ratio(x) | 0.51 | 0.97 | 1.03 | 0.88 | 0.78 | Interest Cover(x) | -2.88 | 10.75 | 16.26 | 5.53 | 2.93 | Total Debt/Mcap(x) | 0.01 | 0.00 | 0.00 | 0.02 | 0.02 |
|
|
|
|
|
|